Summary.-The influence of human serum albumin (HA) on the biological effects of 13 chemotherapeutic agents was studied in vitro in the human leukaemia cell line MOLT-3. On the basis of changes in biological activity influenced by HA, these drugs may be divided into three types. Type I agents include cis-diamminedichloroplatinum (II), 4'-(9-acridinylamino)methanesulphon-m-anisidide, neocarzinostatin, nitrogen mustard, adriamycin, daunorubicin and mitomycin C-drugs whose biological activities are reduced in the presence of HA. The biological activities of Type II drugs (cytosine arabinoside, fluorouracil and actinomycin D) are not influenced by HA. The biological activities of Type III drugs (bleomycin, vincristine and vinblastine) are increased in the presence of HA. These results indicate that serum HA interferes in vitro with certain anticancer agents in terms of biological activity and, probably, clinical effectiveness. HA-drug interaction may be a major factor governing the pharmacology of Type I anticancer agents in man.
How TO DELIVER an effective concentration of an anticancer agent to its site of action is one of the most important considerations in cancer chemotherapy. It is thought that only free drugs (not bound to blood constituents) can pass through the capillary walls of blood vessels to exert biological activity at their specific sites of action (Koch-Weser & Sellers, 1976) . The interaction of anticancer drugs with blood constituents, particularly with serum albumin, should have a major influence on drug pharmacology and efficiency.
The binding of certain anticancer drugs to plasma protein has been quantified in both in vitro and in vivo systems (Linford, 1961; Donigian & Owellen, 1973; DeConti et al., 1973; Cysyk et al., 1977) , but reports on the role of such binding in altering biological activity and therapeutic effects have been few. Dichloromethotrexate (DCM), an antifolate, was shown to have a higher chemotherapeutic index in mice than methotrexate (MTX) (Goldin et al., 1957; Vogel, 1961) . Reevaluation of intermittent schedules revealed that much larger doses of DCM than of MTX were tolerated in man without leucovorin rescue (Fernbach et al., 1979) . Serum levels of DCM measured by RIA were comparable to MTX levels on a molar basis. Using a human cell-culture system containing human serum albumin (HA) we demonstrated that man's ability to tolerate much higher doses of IDCM than of MTX could be explained, at least in part, by DCM's higher affinity to HA, resulting in a decreased unbound fraction, the active cytotoxic form .
These findings indicated the need for studying the interaction between HA and anticancer agents, and prompted us to extend our study of HA-drug interaction to include 13 anticancer agents currently used in man.
MATERIALS AND METHODS
Cell lines.-A human leukaemia cell line, MOLT 3 (Minowada et al., 1972) was used for the experiment. The cells were maintained in suspension in culture flasks containing RPMI 1640 medium (Gibco, Grand Island, NY) with 10% heat-inactivated foetal calf serum (FCS) and antibiotics (penicillin 100 iu/ml and streptomycin 100 jug/ml) and fed with fresh medium 3 times a week. The experimental design was as described previously Effect of prior exposure to HA.-In order to test whether prior exposure of cells to HA influenced drug sensitivity, cells were grown in the presence of 2-5 g/dl of HA for 3 days. The cells were then washed twice with RPMI 1640 to remove HA and resuspended in the medium. These cells were exposed to ID50 of the drugs for 3 days and the percentage inhibition was compared with the numbers of cells which were processed similarly but without HA. All studies were done in triplicate and experiments were repeated at least 3 times.
RESULTS AND DISCUSSION
The ID50 and ID90 values for each drug in the presence and absence of 2-5 g/dl HA are shown in the Table. These drugs were divided into 3 types on the basis of changes in biological activity influenced by HA. In Type I compounds (DDP, AMSA, NCS, HN2, ADM, DNR and MMC) biological activities were definitely reduced by the presence of 2-5 g/dl HA (Fig. 1) . Thus the ID5o concentrations of DDP, AMSA, NCS, HN2, ADM, DNR and MMC were, respectively, 4-l-, 2-8-, 2-7-, 2-1-, 1-8-, 1P7-and 1'5-fold higher than those in the medium containing no HA.
On an ID90 basis, these values were 4 3-, 2-6-, 3*0-, 19-, 1.9-, 2-0-and 1-5-fold, respectively. HA in the medium did not interfere with the biological activities of Type II compounds (Fig. 1) which included Ara-C, FU and AMD. Type III compounds (BLM, VCR and VBL) were those in which biological activities were clearly increased in the presence of HA (Fig. 1) . The decreased biological activity seen in Type I compounds may either be due to HA-drug binding or to other mechanisms, such as inactivation of drugs by HA and decrease in entry of drugs into the cell. Cells pretreated with 2-5 g/dl HA in the medium from Day -3 to Day 0 were found to be more sensitive to each drug than the non-HA-pretreated cells, and did not result in decreased biological effects of Type I drugs or, indeed, of any other agents tested (Fig. 2) . These results suggested that HA did not interact directly with cell membranes to prevent entry of Type I drugs into cells, and that the biological activities of these drugs were reduced by direct HA-drug interaction in the medium. Previous work from this laboratory revealed that equitoxic concentrations of DCM and MTX were bound to HA about 85% and 50%, respectively . DDP was reported to be highly bound to plasma protein (DeConti et al., 1973; LeRoy et al., 1979) and to exert cytotoxic activity in filterable form only (Patton et al., 1978) . AMSA, which is a DNA binder similar to other acridines, was found to bind to rat plasma protein, with about 50% binding with plasma protein 2 h after drug administration (Cysyk et al., 1977) . On the other hand, pyrimidine analogues do not generally bind to plasma protein (Mihich, 1973; Dixon & Adamson, 1965 ). It appears, therefore, that HA's influence on biological activity of Type I compounds is related to moderate to high degrees of binding of drugs to HA in the culture medium. The lack of interaction of Type II compounds is in accord with reports that these compounds do not bind with HA.
It has been reported that BLM has a rapid renal clearance and does not bind with plasma protein (Sikic et al., 1978) . Donigian & Owellen (1973) extensively to oa-and fl-globulins than to albumin on a mol/g basis. Therefore, low binding of vinca alkaloids with HA is consistent with inability of HA to decrease the biological effects of the compounds. The susceptibility of cells exposed to HA before the addition of chemotherapeutic agents tended to be more pronounced with Type III agents (Fig. 2) . The data suggest that, for Type III agents, the direct inhibitory effects on the cell potentiated by HA were more pronounced than any effects produced by the decrease in available free drug. It is also possible that biological changes produced by the macromolecule on intracellular metabolism and/or on the cell membrane were responsible for this observation. We found no clear correlation between molecular weight of a drug and the influence of HA on the biological effects of the drug. Since the biological activity of DDP, which has a lower molecular weight than other drugs evaluated in this study, is most influenced by HA, the molecular weight of the drug does not appear to be a determining factor in HA-drug interaction. The drugs known to bind with DNA tend to be influenced by HA, but there are some exceptions (e.g. NCS).
Since the parent medium contains 10% FCS and antibiotics, it is possible that calf serum albumin interacts with Type I compounds. However, it is estimated that the calf serum albumin constituted only 12-15% of HA. All experiments were done in the presence of 10% FCS and defined concentrations of antibiotics, and significant differences were recognized in the shapes of the drug-produced response curves with or without HA (Fig. 1) important problem, because a small change in binding will increase the proportion of free drug and may produce increased clinical toxicity. Thus, the administration of Type I drugs to patients with hypoalbuminaemia, and the concomitant administration of unrelated drugs when necessary, requires close clinical monitoring. Second, the interaction may be relevant to the clinical effects of the drug given by different schedules. Drug administration has been scheduled either empirically or on the basis of pharmacokinetics and cell-kill kinetics of the drug. In order to achieve the maximal cell kill by an S-phasespecific drug it has been proposed that such a drug be administered not only in an adequate dose, but also with sufficient frequency (Clarkson, 1974) . The continuous infusion of Ara-C is rational in respect to its cell-kill kinetics and to its lack of interaction with HA. On the basis of HA-drug interaction, the drug with high HA-binding capacity may be considered for administration by repeated i.v. bolus rather than by continuous infusion, because continuous infusion may cause successive uptake by plasma protein, leaving little free active drug (KochWeser & Sellers, 1976) . In this context, repeated i.v. bolus administration may be considered for Type I drugs in order to achieve effective concentrations of free drugs. We noted recently that patients tolerated NCS given by continuous 24h infusion at a dose 3 x that given by short 2h infusion (Ohnuma et al., 1978) . These observations may be explained partly by an HA-NCS interaction in plasma.
The results of in vitro drug studies with with cultured cells cannot hastily be extrapolated to the clinical setting without consideration of in vivo pharmacokinetic barriers. Nevertheless, albumin-binding is expected significantly to influence absorption, transport, distribution and excretion of the Type I compounds, in a complex fashion. We consider the HA-anticanceragent interaction as one of the major factors governing the pharmacology of the Type I drug in man.
